Want to see SYBX full AI Analyst Report?
SYBX Stock Chart & Stats
$1.21
$0.02(1.41%)
At close: 4:00 PM EST
$1.21
$0.02(1.41%)
Day’s Range― - ―
52-Week Range$0.54 - $1.87
Previous CloseN/A
Volume234.00
Average Volume (3M)137.73K
Market Cap
$14.88M
Enterprise Value$4.96
Total Cash (Recent Filing)$13.18M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.73
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,248,950
10 Day Avg. Volume12,084
30 Day Avg. Volume137,731
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.16
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetEliminating debt reduces interest and refinancing pressure, giving Synlogic greater financial flexibility while it develops therapies. Positive equity provides some cushion, although the company remains dependent on funding because it has not reached profitability.
Improved Cost ControlThe sharp reduction in losses and operating cash burn indicates substantially lower spending and better cost discipline. If maintained, this can extend available resources and reduce financing pressure while clinical development progresses, despite the absence of commercial revenue.
Funded Clinical RunwayThe large financing provides resources to advance CLD-423 in ulcerative colitis and Crohn’s disease through Phase 2 development. A runway into 2029 may support sustained clinical execution and reduce near-term dependence on additional capital.
Bears Say
No Commercial RevenueThe lack of recurring revenue shows that Synlogic has not yet commercialized its platform and has limited operating leverage. Future value therefore depends heavily on clinical success, regulatory progress, and eventual product adoption rather than an established revenue base.
Persistent Negative Free Cash FlowSynlogic still consumes cash and cannot fund operations through internally generated resources. This creates enduring financing dependence typical of clinical-stage biotechnology and exposes shareholders to future capital raises if development spending or trial requirements increase.
Shrinking Scale And Dilution RiskThe contracted asset base signals substantial erosion of financial scale, while the merger structure gives existing Synlogic holders a small share of the combined company. This limits their economic participation and creates meaningful dilution and transaction-execution risk.
Synlogic News
SYBX FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was $0.54 and its highest was $1.87 in the past 12 months.
What is Synlogic’s market cap?
Synlogic’s market cap is $14.88M.
When is Synlogic’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Synlogic’s earnings last quarter?
Currently, no data Available
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synlogic have?
Synlogic has 12,248,950 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synlogic?
Currently, no hedge funds are holding shares in SYBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Synlogic
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Aptevo Therapeutics
―
SeaStar Medical Holding
―
Cingulate Inc
―
Allarity Therapeutics
―
Ownership Overview
34.63% Insiders
0.04% Mutual Funds
0.19% Other Institutional Investors
65.14% Public Companies and
Individual Investors